Related Experiment Video

Updated: Jun 9, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

[ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy]

P Klener1, P Klener

  • 1Interní klinika, klinika hematologie VFN a 1. LF UK v Praze. pavel.klener@ruk.cuni.cz

Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|September 3, 2010
PubMed

Insights

Protein tyrosine kinases regulate cell functions, but their abnormal activity drives cancer. Small molecule tyrosine kinase inhibitors are effective anti-cancer agents, particularly for CML and certain solid tumors.

Area of Science:

  • Cellular Biology
  • Biochemistry
  • Oncology

Context:

  • Non-receptor protein tyrosine kinases are crucial for physiological cellular processes like growth, proliferation, and motility.
  • Aberrant protein tyrosine kinase activity, due to mutations or translocations, is linked to cancer progression, drug resistance, and metastasis.

Purpose:

  • To review the role of non-receptor protein tyrosine kinases in cellular signaling and cancer.
  • To highlight the therapeutic potential of small molecule tyrosine kinase inhibitors (TKIs) in treating various cancers.

Summary:

  • Small molecule TKIs target aberrantly activated tyrosine kinases (e.g., BCR-ABL1, PDGFRA, PDGFRB), disrupting cancer-promoting signaling pathways.
  • Established TKIs like imatinib, nilotinib, and dasatinib show clinical efficacy in Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
  • Newer generation TKIs, such as dasatinib, exhibit preclinical activity against solid tumors by inhibiting kinases like SRC and EPH.

Impact:

  • TKIs represent established and promising anti-cancer agents, offering targeted therapies for hematologic malignancies and potential treatments for solid tumors.
  • Understanding tyrosine kinase signaling is vital for developing novel cancer therapeutics and overcoming drug resistance.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...